Mirum Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $159,882 | $148,932 | $133,010 | $127,785 |
Gross Profit | 131,002 | 120,594 | 107,473 | 104,364 |
EBITDA | -789,465 | 4,709 | 9,060 | 4,186 |
EBIT | -796,339 | -1,365 | 2,998 | -1,870 |
Net Income | -790,155 | -5,730 | 2,905 | -5,861 |
Net Change In Cash | 159,882 | 148,932 | 133,010 | 127,785 |
Free Cash Flow | -229,427 | 5,467 | 39,494 | 11,914 |
Cash | 324,907 | 296,683 | 282,021 | 228,122 |
Basic Shares | 58,851 | 50,198 | 56,993 | 49,726 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $521,312 | $336,888 | $186,374 | $77,062 |
Gross Profit | 420,728 | 255,245 | 139,335 | 64,688 |
EBITDA | 17,206 | -48,972 | -136,490 | -122,854 |
EBIT | -7,038 | -72,601 | -147,319 | -126,092 |
Net Income | -23,363 | -87,942 | -163,415 | -135,665 |
Net Change In Cash | 521,312 | 336,888 | 186,374 | 77,062 |
Cost of Revenue | -3,349 | |||
Free Cash Flow | 54,873 | 9,332 | -91,053 | -120,414 |
Cash | 296,683 | 222,503 | 286,326 | 28,003 |
Basic Shares | 50,198 | 47,523 | 40,885 | 33,982 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$1.08 |
2025-12-31 | -$0.12 |
2025-09-30 | $0.05 |
2025-06-30 | -$0.12 |